The Latest Cardiac and Vascular News
Salt Lake City, UT, Nov. 08, 2022 (GLOBE NEWSWIRE) — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without standard modifiable heart risk factors who experience a heart attack are common and more likely to fare better than heart-attack patients with known risk […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 11th Annual Meeting, “The CEO + CFO Roundtable.” The conference is taking place this week, November 7-10, 2022, at the Hyatt Regency Hotel in Chicago. As part of Cardio Diagnostics’ sponsorship, Meesha Dogan, CEO, […]
– ARO-APOC3 decreased triglycerides by 86%, and non-HDL-C by 45% while increasing HDL-C by 99% in patients with severe hypertriglyceridemia – ARO-ANG3 decreased triglycerides by 59%, LDL-C by 32%, and was associated with a relative reduction in liver fat fraction in patients with mixed dyslipidemia – Olpasiran reduced lipoprotein(a) levels […]
-RBT-1 interim results from a randomized double-blind placebo-controlled study showed statistically significant reductions in days on ventilator and days in ICU. 30-day hospital readmission was reduced by greater than 90% -(<0.0027)- -RBT-1 was recently granted Fast Track Designation from U.S. FDA- -Pivotal Phase 3 study of RBT-1 to be initiated […]
SAN DIEGO, Nov. 7, 2022 /PRNewswire/ — NovoMedix, LLC (“NovoMedix”), a biotechnology company developing novel, multi-pathway modulators for fibrosis and cancer, today announced the presentation of new preclinical data on NMX2 at the 2022 American Heart Association Scientific Session, being held November 5-7, 2022 in Chicago, Illinois. The presentation is titled, “Dual AMPK Activator/mTOR Inhibitor […]
ROCKVILLE, M.D. and SUZHOU, China, Nov 6, 2022 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the results of a phase 3 clinical study (CREDIT-1) of tafolecimab (IBI306), a […]
Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001) Median time to conversion was 17 minutes for patients treated with etripamil – three times faster than placebo Analyses of pooled data show […]
Olpasiran Reduced Lipoprotein(a) Levels by More Than 95% in Patients With Established ASCVD Amgen is Initiating a Phase 3 Cardiovascular Outcomes Trial Based on These Results Data Simultaneously Published in the New England Journal of Medicine THOUSAND OAKS, Calif. , Nov. 6, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its […]
Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels HAV may address many limitations of current standard of care grafts used in CABG procedure DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered […]
— Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients — — PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients — DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 07, 2022 […]
